USD
Growth hormone research peptides are not one uniform class. Catalogs may group growth hormone-releasing hormone analogs, growth hormone secretagogues, recombinant growth hormone and insulin-like growth factor analogs together because they relate to the GH–IGF-1 axis. Their identities and signaling points remain distinct.
- Classify by signaling family before comparing strength.
- Do not use “HGH peptide” as a substitute for an exact chemical identity.
- Verify whether a listing is a single compound, recombinant protein or blend.
Four catalog families that are often mixed together
| Family | Examples found in research catalogs | Identity question |
|---|---|---|
| GHRH-related | CJC-1295, sermorelin, tesamorelin | Which analog and which modification? |
| Secretagogues | Ipamorelin, GHRP-2, GHRP-6, hexarelin | Which receptor agonist and sequence? |
| Growth hormone | Somatropin / HGH 191AA | Is the listing a protein rather than a short peptide? |
| IGF-related | IGF-1 LR3, IGF-DES | Which insulin-like growth factor analog? |
A search for “growth peptides” can retrieve all four groups. That makes it useful for discovery but weak for final selection. The protocol should name the molecular family and exact analyte before a researcher compares pack size or price.
How to read a growth-signaling listing
- Expand the SKU into the full product name.
- Identify whether the compound is GHRH-related, a secretagogue, growth hormone or IGF-related.
- Record modifications such as DAC, LR3 or DES exactly as shown.
- Check strength and quantity as separate catalog attributes.
- Review documentation for the specific lot rather than relying on category-level wording.
The Growth & Signaling Research collection provides a starting point. Examples include CJC-1295 with DAC, a CJC-1295 No DAC and Ipamorelin blend, and Tesamorelin. These links show catalog identity and packaging; they do not make the compounds equivalent.
Evidence limits matter
Reviews of the GH–IGF-1 axis distinguish the major compound families and also note uneven clinical evidence and safety data. A mechanistic paper may support how a receptor pathway is studied without supporting a commercial claim. Keep preclinical findings, controlled human research and catalog descriptions clearly separated.
Use the NOVABIO naming guide when an abbreviation is unfamiliar, or contact support for a listing-specific question.
Frequently asked questions
What are growth hormone secretagogues?
Growth hormone secretagogues are compounds studied for activation of the growth hormone secretagogue receptor and downstream growth hormone release. Examples in the literature include ipamorelin, GHRP-2 and GHRP-6. They are different from GHRH analogs, recombinant growth hormone and insulin-like growth factor analogs.
Is CJC-1295 the same as ipamorelin?
No. CJC-1295 is described as a growth hormone-releasing hormone analog, while ipamorelin is a growth hormone secretagogue receptor agonist. Some catalogs sell them together as a blend, but a combined listing does not erase the separate identity, mechanism or evidence base of each component.
What should researchers verify on a GH-axis product page?
Verify the full compound name, modification, listed strength, vial count and whether the item is a single compound or blend. Terms such as DAC, LR3, DES and 191AA carry identity information. The category name alone is not precise enough for procurement or experimental records.
Sources
- PubMed: GH–IGF-1 axis peptide landscape (accessed 2026-08-27)
- PubMed: ipamorelin pharmacology (accessed 2026-08-27)
- PubMed: CJC-1295 clinical pharmacology (accessed 2026-08-27)
Research-use notice: This article explains catalog identity and published research. It is not medical advice, a treatment claim or a dosing guide. NOVABIO catalog products are presented for laboratory research and are not represented here as approved for human use.